mip-1β

Maraviroc (UK-427857, Selzentry) belongs to small molecule drugs and is a C-C chemokine receptor 5 antagonist with oral activity and selectivity. This compound is used for the treatment of HIV-1 infection and has also shown anti-inflammatory, neuroprotective, and potential antitumor synergistic effects in research.

TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).

BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist with a Ki of 1 nM for human CCR1, exhibiting 250-fold selectivity over CCR2, CCR5, and CXCR4.

TAK-220 is a selective and orally bioavailable CCR5 antagonist with IC50 values of 3.5 nM for RANTES binding inhibition and 1.4 nM for MIP-1α binding inhibition to CCR5.

MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA, characterized by excellent biodistribution and efficient targeting of tumor sites. In applications, it is isotopically labeled (131I labeled) to act as an imaging probe, indicating tumor progression. The compound 131I-MIP-1095 shows high renal uptake in mice.

MIP-1072 is the prostate-specific membrane antigen inhibitor.

MIP-1095 is the prostate-specific membrane antigen inhibitor.

MIP-1095 I-131 is a small molecule PSMA inhibitor.

Iofolastat I 123 is a diagnostic agent under investigation in clinical trial NCT00992745 (A Phase I Pilot Study in Subjects With Metastatic Prostate Cancer).

MIP-1095 I-123, as a radiotracer, is under investigation in clinical trial NCT00712829 (Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).

BC-1293 is an inhibitor of the E3 ligase subunit FBXO24 that acts by disrupting the interaction between FBXO24 and aspartyl-tRNA synthetase (DARS2). BC-1293 treatment results in increased levels of DARS2, showing its capacity to stabilize this essential enzyme. Furthermore, BC-1293 elevates levels of cytokines including IL-1β, IL-9, MIP-2, and TNF-α in murine models, thereby demonstrating immunostimulatory activity with potential relevance to immune modulation research.

Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.

KRP-109 is a neutrophil elastase (NE) inhibitor known for its ability to alleviate lung inflammation. In mouse models, KRP-109 has been shown to increase survival rates and reduce both the number of neutrophils in alveolar walls and the severity of inflammation. It significantly decreases cell and neutrophil counts, along with cytokine levels (such as interleukin 1β and macrophage inflammatory protein 2) in bronchoalveolar lavage fluid. KRP-109 is applicable for investigating severe pneumonia.

TLR4 agonist-1 (TEA, compound 17a) is a potent activator of Toll-like Receptor 4 (TLR4) and prompts the production of MIP-1β in RAW 264.7 and MM6 cells [1].

TLR4 agonist-1 (compound 17a) is a potent activator of Toll-like Receptor 4 (TLR4), stimulating MIP-1β production in RAW 264.7 and MM6 cells [1].